Live News

Trastuzumab Rezetecan: First Approval

Trastuzumab rezetecan (Avida 艾维达®) is a human epidermal growth factor receptor 2 (HER2)...

Drugs

0 0

Dordaviprone: First Approval

Dordaviprone (MODEYSO™) is a protease activator being developed by Chimerix for the treatment of various cancers, in...

Drugs

0 0

Can Gene Therapy Transform the Treatment Landscape of Posterior Segment Eye Diseases? A Comprehensive Review of Recent Advancements

Posterior segment eye diseases (PSEDs) encompass a diverse group of conditions affecting the retina, choroid, optic nerve,...

Drugs

0 0

Elinzanetant: First Approval

Elinzanetant (Lynkuet™) is a non-hormonal, small-molecule neurokinin 1 (NK1) and 3 (NK3) antagonist being developed ...

Drugs

0 0

Taletrectinib: First Approval

Taletrectinib 己二酸他雷替尼膠囊 [DOVBLERON 达伯乐...

Drugs

0 0

Donidalorsen: First Approval

Donidalorsen (DAWNZERA™) is a first-in-class, RNA-targeted antisense oligonucleotide (ASO), developed by Ionis Pharm...

Drugs

0 0

Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies

HER2 overexpression/amplification is a well-established oncogenic driver across several tumor types and has emerged as a t...

Drugs

0 0

Tolebrutinib: First Approval

Tolebrutinib (CENRIFKI®) is an orally available, brain-penetrant small molecule inhibitor of Bruton’s tyrosine ...

Drugs

0 0

Paltusotine: First Approval

Paltusotine (PALSONIFY™) is a non-hormonal, orally active selective somatostatin receptor 2 (SSTR2) agonist that con...

Drugs

0 0

Elamipretide: First Approval

Elamipretide (Forzinity™) is a mitochondrial cardiolipin binder being developed by Stealth BioTherapeutics for the t...

Drugs

0 0

Imlunestrant: First Approval

Imlunestrant (Inluriyo™), an oral, selective, estrogen receptor (ER) degrader (SERD), is being developed by Eli Lill...

Drugs

0 0

Brensocatib: First Approval

Brensocatib (BRINSUPRI™), an oral, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), is being d...

Drugs

0 0

Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review

Glucagon-like peptide-1 receptor agonists (GLP-1RAs)—along with the dual glucose-dependent insulinotropic polypeptid...

Drugs

0 0

Rilzabrutinib: First Approval

Rilzabrutinib (WAYRILZ™) is a small-molecule, reversible, highly specific, covalent BTK inhibitor being developed by...

Drugs

0 0

Zeprumetostat: First Approval

Zeprumetostat (艾瑞璟), an oral, selective, small molecule inhibitor of enhancer of zeste homolog 2 (EZH...

Drugs

0 0

Developments in Pharmacotherapy for Obstructive Sleep Apnoea: Unlocking the Potential for Targeted Treatment

Obstructive sleep apnoea (OSA) is a common, chronic respiratory disorder associated with major co-morbidity and adverse sa...

Drugs

0 0

Cosibelimab: First Approval

Cosibelimab (UNLOXCYT; cosibelimab-ipdl) is an anti-PD-L1 antibody developed by Checkpoint Therapeutics for the treatment ...

Drugs

0 0

Iparomlimab and Tuvonralimab: First Approval

Iparomlimab and tuvonralimab (齐倍安®) is a bifunctional combination of anti-programmed death recep...

Drugs

0 0

Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

Neurogenic lower urinary tract dysfunction (NLUTD), a complex abnormality caused by multiple neurologic disorders, is a&am...

Drugs

0 0

The Potential of RNA Therapeutics in Treating Cardiovascular Disease

Despite significant advances in cardiology over the past few decades, cardiovascular diseases (CVDs) remain the leading ca...

Drugs

0 0

Acoramidis: First Approval

Disassociation of transthyretin (TTR) has been identified as a key step in the pathology of TTR amyloid cardiomyopathy, wh...

Drugs

0 0

PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) share a complex and multifactorial relations...

Drugs

0 0

Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort Study

In recent years, use of glucagon-like peptide-1 receptor agonists (GLP-1RA) has exponentially increased due to their benef...

Drugs

0 0

Crinecerfont: First Approval

Crinecerfont (CRENESSITY™) is a corticotropin releasing factor type 1 (CRF1) receptor antagonist developed by Neuroc...

Drugs

0 0

Therapeutic Potential of Centhaquine Citrate, a Selective Alpha-2B Adrenoceptor Agonist, in the Management of Circulatory Shock

Shock is a life-threatening condition marked by inadequate tissue perfusion and organ dysfunction with high morbidity and ...

Drugs

0 0

Garadacimab: First Approval

Garadacimab (Andembry®) is a fully human IgG4/lambda recombinant monoclonal anti-activated Factor XII antibody being ...

Drugs

0 0

Catumaxomab: First Approval

Catumaxomab (Korjuny®) is a first-in-class bispecific trifunctional rat-mouse hybrid monoclonal antibody currently un...

Drugs

0 0

Differentiating IL-23 Inhibitors in Crohn’s Disease

Interleukin-23 (IL-23), a member of the IL-12 family of cytokines, plays a critical role in intestinal homeostasis and inf...

Drugs

0 0

Datopotamab Deruxtecan: First Approval

Datopotamab deruxtecan (DATROWAY®) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug co...

Drugs

0 0

Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly

The global population aged 80 years and older will reach approximately half a billion in the coming years, and cardiovascu...

Drugs

0 0

Categories

Channels

SCI Abstract